Answers are grounded in this paper and cite their sources.
Although leprosy burden has declined in Ethiopia, evidence on post-treatment clinical outcomes and morphological indices among multibacillary (MB) patients remains limited. To assess clinical outcomes, bacterial and morphological index changes, and factors associated with unfavourable outcome among MB leprosy patients completing multidrug therapy (MDT) at ALERT Hospital, Addis Ababa, Ethiopia. A retrospective case series was conducted among all consecutive MB leprosy patients who completed the recommended MDT at ALERT Hospital between November 1, 2020 and November 30, 2025. Data were extracted from medical records using a structured checklist and analyzed using SPSS version 27. Changes in the highest-site bacterial index (BI) and morphological index (MI) before and after MDT were assessed using the Wilcoxon signed-rank test. Bivariable and multivariable logistic regression analyses were performed to identify factors associated with composite unfavourable end-of-MDT outcome. Statistical significance was set at p < 0.05. Of 148 records screened, 107 patients met the eligibility criteria and were included in the final analysis. The median age was 30 years (IQR: 25–36), and most participants were male (65.4%) and aged 15–44 years (89.7%). At treatment completion 54 patients (50.5%) met the criteria for a composite unfavourable end-of-MDT outcome. Although both BI and MI declined significantly after MDT (BI: z = -7.85, p < 0.001; MI: z = -7.01, p < 0.001), substantial residual bacteriological activity persisted, with 64.5% having BI ≥ 2 and 86.0% having MI 0–10 at treatment completion. In multivariable analysis, a documented history of immunological reaction was independently associated with the composite unfavourable end-of-MDT outcome (AOR 3.40; 95% CI 1.23–9.39; p = 0.019). Half of the included patients met the study’s composite definition of an unfavourable end-of-MDT status, although BI and MI decreased significantly during treatment. Because the composite endpoint included residual clinical or bacteriological abnormalities and the study did not assess relapse or drug resistance, these findings should not be interpreted as evidence that standard MDT is ineffective. They support improved end-of-MDT documentation and risk-stratified post-treatment surveillance, particularly among patients with immunological reactions.
No takes yet. Share an insight, caveat, or question.
Temesgen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: